XPhyto Therapeutics to acquire 3a-diagnostics GmbH

XPhyto Therapeutics Corp. signed a definitive agreement to acquire 3a-diagnostics GmbH for EUR 3.9 million. The acquisition is planned to close on or around October 31, 2021.

“We strongly believe that this acquisition will result in powerful synergies and further feed XPhyto's diagnostic pipeline, supporting our long-term commercial growth plans.”biospace.com

• 1 source
• biospace.comXPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio - BioSpaceAnnalee ArmstrongJul 20, 2021

Summarized from public sources; check the original articles before acting on it.